MedTrace Logo

The Role of Melatonin as an Adjuvant Therapy in Childhood Pneumonia

NCT06949904 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-04-29

No results posted yet for this study

Summary

The goal of this study is to compare the mean length of hospital stay between children with pneumonia receiving melatonin as an adjuvant therapy and those receiving standard of care alone.

The hypothesis is that combining oral melatonin with standard treatment can reduce the length of hospital stay as compared to standard of care alone.

The control group will receive standard treatment (antibiotic) while the intervention group will receive standard treatment plus melatonin for 14 days.

Conditions

  • Pneumonia Childhood

Interventions

DRUG

Melatonin

1 mg/dose in infants and 2.5 to 3mg/dose in children three times a day for 14 days

Sponsors & Collaborators

  • Mian Muhammad Hassan Ahmed

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
1 Month
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-31
Primary Completion
2025-12-31
Completion
2026-01-31

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06949904 on ClinicalTrials.gov